Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...

US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...

A comprehensive study published in the journal of BMJ Rheumatic & Musculoskeletal Diseases focused on the prevalence and risk ...

The global Psoriatic Arthritis (PsA) Treatment Market is expected to grow from USD 11,973.7 million in 2024 to USD 25,375.6 ...

Overactive bladder (OAB) is associated with arthritis, with a positive association seen after adjustment for all co ...